Skip to main content
LSL Pharma Group Inc. logo

LSL Pharma Group Inc. — Investor Relations & Filings

Ticker · LSL ISIN · CA50190N1042 TSXV Manufacturing
Open in API
Filings indexed 194 across all filing types
Latest filing 2026-04-15 Regulatory Filings
Country CA Canada
Listing TSXV LSL

About LSL Pharma Group Inc.

https://www.groupelslpharma.com/en

LSL Pharma Group Inc. is an integrated pharmaceutical company focused on the development, manufacturing, and commercialization of specialized life sciences products. The company operates multiple manufacturing facilities dedicated to producing a diverse portfolio, including sterile pharmaceutical products, natural health products (NHPs), cosmetic products, food supplements, and vitamins, often in tablet and capsule formats. LSL Pharma Group functions as a Contract Development and Manufacturing Organization (CDMO) for natural and pharmaceutical segments. The company leverages its integrated capabilities to serve domestic and international markets, including strategic distribution agreements aimed at supplying high-quality pharmaceuticals to alleviate drug shortages in hospital environments.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 80% confidence The document is a corporate press release announcing LSL Pharma’s participation in an investor conference, with event details and webcast links. It does not contain financial results (earnings), a formal investor presentation deck, AGM materials, or any regulatory-specific filing (e.g., proxy, dividend notice, share issuance). It falls into the miscellaneous category for general announcements that do not fit more specific classes.
2026-04-15 English
Notice of the meeting and record date - French.pdf
Proxy Solicitation & Information Statement Classification · 78% confidence The document is an electronic transmission from the transfer agent confirming the sending of the notice of record date and meeting date for the issuer’s upcoming annual and special shareholders’ meeting. It is not the full meeting materials or proxy circular itself, but it falls under the proxy solicitation process as the required notice to shareholders and intermediary (CDS) of meeting and record dates. This aligns with “Proxy Solicitation & Information Statement (Code: PSI)” – materials sent to shareholders in advance of a vote. Therefore, it should be classified as PSI.
2026-04-13 French
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 78% confidence The document is a TSX Trust Company letter confirming the record date and meeting date for LSL Pharma Group Inc.’s upcoming Annual General and Special Meeting of Security Holders. It is an administrative notice to exchanges and regulators rather than the full AGM materials or proxy statement itself, contains no slides or financials, and is not reporting voting results. It does not solicit proxies or present executive changes. Therefore it falls into the general regulatory announcement category (fallback).
2026-04-13 English
Notice of the meeting and record date - French.pdf
Regulatory Filings Classification · 75% confidence The document is a TSX electronic transmission confirming the notice of record date and meeting date for the annual and extraordinary general meeting. It is not the actual AGM presentation or proxy materials, nor is it reporting vote results. It is a regulatory notification to exchanges and commissions, fitting the fallback category for miscellaneous regulatory announcements. Therefore, it is best classified as a Regulatory Filing (RNS).
2026-04-13 French
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 80% confidence The document is a TSX Trust Company letter confirming the sending of a Notice of Record and Meeting Dates for LSL Pharma Group Inc.’s upcoming Annual General and Special Meeting. It does not include AGM presentations or the proxy materials themselves, nor does it present financial results or other management commentary. It is a formal regulatory notice to exchanges/commissions regarding meeting logistics. This best fits the catch-all “Regulatory Filings” category for miscellaneous regulatory submissions that don’t fall under a more specific type.
2026-04-13 English
News release - English.pdf
Regulatory Filings Classification · 75% confidence The document is a press release announcing a commercial supply agreement (binding term sheet) between subsidiaries of LSL Pharma and Instapill for OTC products, including forward-looking statements. It does not present financial results (not an ER, IR, or 10-K), nor is it requesting shareholder votes (not PSI/DVA), nor is it governance or management changes. It is a general corporate announcement with no specific category, so it falls into the fallback “Regulatory Filings” category (RNS).
2026-04-09 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.